Clayton Partners’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
Other funds holding AZN
Clayton Partners's AZN Position: Q3 2026 in Review
Clayton Partners reduced its AstraZeneca (AZN) stake by 0.3% in Q3 2026, selling an estimated $11.7K and leaving 23,142 shares worth $3.74M. The position accounts for 2.43% of the portfolio, ranked #13.
Clayton Partners first reported a position in AZN in Q1 2024 and has held it in 11 quarters since. The position peaked at $4.56M in Q1 2026. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.
- Clayton Partners held 23,142 shares of AstraZeneca worth $3.74M as of Q3 2026.
- Clayton Partners sold 70 AstraZeneca shares in Q3 2026, an estimated $11.7K.
- AstraZeneca made up 2.43% of Clayton Partners's portfolio in Q3 2026, its #13 holding.
- Clayton Partners first reported a position in AstraZeneca in Q1 2024 and has held it in 11 quarters since.
- Clayton Partners's AstraZeneca position peaked at $4.56M in Q1 2026.
- 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.
Based on Clayton Partners's 13F filing for Q3 2026, filed 16 Nov 2026.